Spastic Paraplegia, Hereditary

Badminton 10月26日清晨，阳光明媚，微风徐徐，正是运动的好时节。在李氏大药厂控股有限公司（简称“李氏大药厂”或“集团”，股份编号：00950）南沙基地的羽毛球场上，一场别开生面的基地团体赛正悄然拉开帷幕。 本次对抗赛旨在促进南沙基地与合肥基地间的友好交流，同时增强公司员工的身心健康，提升团队凝聚力，丰富企业文化生活的坚实桥梁。 赛事设置了男子单打、男子双打、女子单打、女子双打及混合双打等多个比赛项目，全方位展现参赛队员的卓越技艺与默契配合。每一场对决，都是速度与力量的华丽绽放，策略与智慧的精妙演绎，让人目不暇接，热血沸腾。 · “博士杯”对抗赛 随着裁判的一声哨响，比赛正式打响。第一场比赛是男子单打，由南沙基地队林嘉发对阵合肥基地队吴则红。只见林嘉发猛地一跃，高高举起球拍，手腕一翻，羽毛球如同脱弦之箭般飞出，直奔对方底线，南沙基地队率先拿下一分！ 随着比赛的进行，双方你来我往，攻防转换迅速，每一个回合都让人目不暇接，让现场观众们大饱眼福。紧接着南沙基地队的两轮比赛连连得分，观众席上，加油声此起彼伏，每一次精彩的扣杀都会引发一阵热烈的掌声。最终南沙基地团队获得第一场比赛积分。 在第二场的男双比赛中两个基地队的队员们迅速进入状态，他们身着统一的队服，手持球拍，目光坚定而充满斗志。球场上，羽毛球如流星般穿梭，每一次挥拍都伴随着力量与速度的碰撞，让人目不暇接。观众席上大家不仅为各自的基地的队伍加油助威，也不时为对方队伍的精彩表现鼓掌喝彩。这种友好而激烈的竞争氛围，正是兆科药业所倡导的企业文化的生动体现。 经过五轮的精彩对决，在第六场男子单打比赛由南沙基地队李博士对阵合肥基地队吴则红，双方你来我往，互不相让。每当合肥基地队同事试图拉开差距时，李博士总能凭借顽强的意志力和精准的判断，将比分追上。现场的气氛因此变得异常紧张，观众们的心也随之提到了嗓子眼。李博士的努力拼博精神很好的诠释了兆科的精神。通过自身的努力拼搏鼓励我们——只要心中有梦，勇于拼搏，就没有什么是不可能的。 这场比赛不仅是一场技术的较量，更是一场意志的比拼。他们用汗水和努力诠释了体育精神的真谛。无论比赛结果如何，这场对决都将成为一段佳话。它让我们看到了体育竞技背后的人性光辉，也激发了更多人对于生活的态度和追求的思考。不仅是一次技术的展现，更是一次心灵的洗礼。 经过一天的数轮激战，最终合肥基地队凭借更加出色的团队配合和个人能力，赢得了本场比赛的胜利。但比分的背后，更重要的是两队队员在比赛中展现出的顽强拼搏、团结协作的精神风貌。他们用汗水和努力诠释了“友谊第一，比赛第二”的体育精神。 赛后，我们还进行了简单而温馨的颁奖仪式。由李博士为本次比赛做总结并进行颁奖。获奖队伍在掌声和欢呼声中接过奖杯和奖品，他们的脸上洋溢着自豪和喜悦。同时，公司也特别设置了不同的个人奖项，以表彰所有参赛队员的辛勤付出和卓越贡献。 随着颁奖仪式的结束，本次羽毛球团体赛也圆满落下帷幕。但比赛所带来的影响却远远没有结束。它不仅增强了南沙基地与合肥基地之间的联系和友谊，也为公司员工提供了一个展示自我、锻炼身体的平台。相信在未来的日子里，大家会将这份团结、拼搏、进取的精神带到工作中去，为兆科药业的发展贡献更多的力量！ 往期回顾 ◆  Matrix Breaking News 2024 | 第三期（上）：袁勇贵教授解读：急性心力衰竭患者出院后抑郁症对预后的影响 ◆  Matrix Breaking News 2024 | 第三期（下）：国际心脏病学专家Francesco Tona教授解读 ◆  精彩会议回顾 | 2024年ALS病例魔方第4期：遗传性痉挛性截瘫/ALS与神经心理学 ◆  不忘初心跟党走，廉洁自律树新风——合肥市委党校第66期中青班第5调研组莅临调研 关于李氏大药厂 - 亞太地區最具創新力的上市企業 - 李氏大药厂控股有限公司（简称“李氏大药厂”或“集团”, 股份编号: 00950）成立于1994年，是一家结合了研发驱动和市场导向的生物医药集团公司，总部位于香港。李氏大药厂于2002年7月在香港联合交易所（简称：“港交所”）创业板上市，并于2010年5月成功转至港交所主板上市。李氏大药厂在中国大陆拥有两大综合性生产研发基地，即：兆科合肥基地（位于安徽省合肥市高新区）和兆科广州基地（位于广东省广州市南沙区），目前员工总数超过1100人。 李氏大药厂立足中国大陆，放眼国际，通过坚实和稳固的投入建设，全面覆盖整合了药物研发、临床研究、药政注册、生产制造、销售与市场推广等各个环节。集团集中于心血管科、妇科与产科、儿科、罕见病、肿瘤科、皮肤科、精神科等多个重要疾病领域开发不同阶段的专利新药和高端仿制药。李氏大药厂与20余家国际公司建立了广泛的合作关系，目前在中国大陆、香港、澳门及台湾地区推广及销售25种包含专利新药、仿制药物及授权引进的国外已上市进口药品。 李氏大药厂现有超过40个处于不同开发阶段的产品，既有自主研发产品，也有通过来自美国、欧洲及日本等公司通过授权引进进行研发、生产以及商业化的产品。 李氏大药厂的使命是通过提供治疗各种疾病的创新产品，以改善患者健康及提高生活质量，成为亚洲一家成功的生物医药集团。 下滑查看更多 免责声明：本公众号发布或转载企业宣传资讯，仅供读者参考之用，并不构成收购、购买或认购依据，并不构成任何个人化的投资劝诱或建议。因本公布全部或任何部分内容而产生或因倚赖该等内容而引致的任何损失不承担任何责任。 企业文化公共关系部出品 图片来源：比赛现场 撰稿：吴冬兰 排版：樊扬波 审核：李星辰 与“李”同行 招商热线 020-39062882

行业动态速览 热点聚焦 01 只有一个患者的临床试验！AAV基因治疗对抗无药可治的超罕见绝症 痉挛性截瘫50型（spastic paraplegia type 50，SPG50）是一种超罕见的疾病，全球患儿数量只有约80人，而在加拿大仅有迈克尔一人被报道患有SPG50。SPG50患者会经历发育迟缓、言语功能障碍以及进行性的四肢瘫痪，通常活不到成年阶段。 在2022年，迈克尔参与了以AAV为基础的SPG50基因疗法临床试验，同时他也是这项试验唯一的患者。 这项1期临床试验的结果已经以“AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient”为题，发表在《自然-医学》上，结果支持了基因疗法拯救迈克尔计划的初步成功。 推荐阅读：只有一个患者的临床试验！对抗无药可治的超罕见绝症，7岁的他迎来治愈曙光 02 利用mRNA瞬时构建TCR-T细胞，治疗晚期难治性高MSI结直肠癌患者！ 结直肠癌（CRC）是全球第三大常见癌症，尽管局部性 CRC 生存率高，但转移性CRC的5年生存率仅约为11%。 近期，挪威奥斯陆大学医学院研究团队报道了在患有 LS 和晚期转移性 MSI-H CRC 的患者中，首次使用 mRNA 电穿孔进行瞬时表达 Radium-1 TCR 在临床患者中应用，相关文章以简报形式，发表在Cell ASGCT系列杂志《Molecular Therapy》上。 推荐阅读：利用mRNA瞬时构建TCR-T细胞，治疗晚期难治性高MSI结直肠癌患者！ 03超70%患者达主要终点！潜在“first-in-class"CAR-T疗法积极临床结果公布 近日，Cartesian Therapeutics宣布了其在研mRNA细胞疗法Descartes-08在全身性重症肌无力（MG）患者中的2b期临床试验的积极顶线结果。 推荐阅读：超70%患者达主要终点！潜在“first-in-class"CAR-T疗法积极临床结果公布 04 CDE公开征求意见！规范腺相关病毒载体基因治疗产品非临床研究 近日，中国国家药品监督管理局（NMPA）药品审评中心（CDE）发布了《腺相关病毒载体基因治疗产品非临床研究技术指导原则（征求意见稿）》，旨在规范并促进腺相关病毒（AAV）载体基因治疗产品的非临床研究，为该类产品的临床试验和上市提供科学依据。 推荐阅读：CDE公开征求意见！规范腺相关病毒载体基因治疗产品非临床研究 创新突破 01 AAV递送工程，最新Science！ 美国怀特海德生物医学研究所Jonathan S. Weissman和MIT/哈佛大学Sonia M. Vallabh等人开发了一种名为CHARM的紧凑表观基因组编辑器，单个AAV就能实现对其的有效递送。在小鼠实验中，CHARM可以敲低全脑中80%以上的朊病毒基因，同时不会改变潜在的DNA序列。该编辑器可以在沉默靶标后实现自我沉默，从而限制长期表达的潜在不利影响。CHARM代表了一种治疗模式，可应用于由有害蛋白质的毒性积聚引起的一系列其他疾病。因此，CHARM最终可能对人类产生类似于碱基编辑、先导编辑等工具的巨大影响。推荐阅读：AAV递送工程，最新Science！ 02 减毒病毒疗法助力癌症治疗！ 近日，一篇发表在国际杂志Journal of Clinical Investigation上题为“An attenuated lymphocytic choriomeningitis virus vector enhances tumor control in mice partly via IFN-I”的研究报告中，来自美国西北大学等机构的科学家们通过研究发现，一种减毒的淋巴细胞性脑膜脊髓炎病毒（LCMV）能够有效清除小鼠体内的肿瘤，并使幸存小鼠对后续肿瘤发展具备更强抵抗力。 研究结果揭示了特殊LCMV载体的强大抗肿瘤效应，并揭示了其抗肿瘤疗效背后的多种分子机制，为癌症治疗提供了新思路。 推荐阅读：减毒病毒疗法助力癌症治疗！   03 苏州儿童医院团队鉴定新的神经母细胞瘤超级增强子 近日，苏州大学附属儿童医院潘健和张子木团队 在 Neuro-Oncology 上发表题为 Super-enhancer-driven IRF2BP2 enhances ALK activity and promotes neuroblastoma cell proliferation 的文章， 鉴定出一个由NB主转录因子簇MYCN, MEIS2和HAND2 调节激活的新SE区域，导致靶基因IRF2BP2的异常高表达。IRF2BP2能够与该NB主转录因子簇之间形成正反馈回路，从而在NB中建立稳定持续的高水平IRF2BP2的表达。此外，IRF2BP2还能够与先驱因子AP-1家族成员通过调节NB易感基因ALK的染色质可及性，维持NB细胞增殖与存活。这项研究为NB生物学提供了新的见解，并有可能为NB下调ALK提供替代策略。 推荐阅读：苏州儿童医院团队鉴定新的神经母细胞瘤超级增强子 资本速递 01 14.5亿欧元！GSK与mRNA巨头达成协议 7月4日，葛兰素史克(LSE/NYSE: GSK) 与 CureVac N.V. (Nasdaq: CVAC)宣布，两家公司已将现有合作重组为一项新的授权协议，使双方能优先投资及专注各自的mRNA开发活动。 根据协议条款，CureVac将获得4亿欧元的预付款，以及至多10.5亿欧元的开发、监管和销售里程碑以及分层版税，累计近15亿欧元（117.68亿人民币，以最新汇率计算）的款项。 根据新的协议条款，GSK将全面负责以上候选疫苗的开发和生产。GSK将拥有全球商业化候选疫苗的权利。 推荐阅读：14.5亿欧元！GSK与mRNA巨头达成协议 02 1.7亿美元B轮融资！创新基因疗法注册性试验已启动 近日，眼科基因治疗公司Beacon Therapeutics宣布已完成1.7亿美元的 B轮融资。该融资由Forbion领投，TCGX和Advent Life Sciences参与，现有投资者Syncona Limited、Oxford Science Enterprises、牛津大学也参与其中。 这些资金将用以支持Beacon用于治疗X连锁视网膜色素变性（XLRP）的主打在研基因疗法AGTC-501的持续临床开发，并支持该公司的干性老年性黄斑变性（dAMD）项目的1/2期临床试验。 推荐阅读：1.7亿美元B轮融资！创新基因疗法注册性试验已启动 03 Cartesian LNP-mRNA细胞疗法临床成功，新获融资1.3亿美金！ 近日，Cartesian Therapeutics宣布签订了一份证券购买协议，用于私人投资公开股权（“PIPE”）融资，预计将为公司带来大约1.30亿美元的总收益。 推荐阅读：Cartesian LNP-mRNA细胞疗法临床成功，新获融资1.3亿美金！ 参考资料： 1.https://mp.weixin.qq.com/s/pbFanDicHXsfZAAXnHZW7Q 2.https://mp.weixin.qq.com/s/GkEznBO7lvdlTThW362Erg 3.https://mp.weixin.qq.com/s/b-q0nD0P1VgnX7wlv8URnA 4.https://finance.sina.com.cn/stock/med/2024-07-07/doc-incchkam5612250.shtml 5.https://mp.weixin.qq.com/s/TO5oI7Nw1cz1tu5WkVFgbw 6.https://mp.weixin.qq.com/s/1lMb-HSL-sia6Aho0qUKCw 7.https://mp.weixin.qq.com/s/7z3SMvOeAFlrZYfdXw3kPw 8.https://mp.weixin.qq.com/s/gT_omNuemkJLTux5e6Bhjw 9.https://mp.weixin.qq.com/s/sfYhDx1ZdkS4RWdPF_oiBw 10.https://mp.weixin.qq.com/s/T9swMSo3FHpn7wrWK1xHWg 关于派真生物

Reported Full Year 2023 total revenues of 2% growth at €48.5 million Secured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the PIF Positioned for strong performance in 2024, driven by new and existing Pharma business and solid Diagnostic growth in line with industry standards; guidance of FY2024 total revenue growth between 10-15% Ongoing strategic alternatives process focused on sustainable long-term value creation for the benefit of its stakeholders CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update. “In 2023, we focused on strategic growth – strengthening our Diagnostic portfolio and introducing new data and wet lab solutions to accelerate drug discovery, development, and commercialization for Pharma. We expanded our partnership model with a joint venture in Saudi Arabia, securing a $30 million investment and additional milestone payments. However, delays in Pharma program timelines impacted our 2023 revenue. Looking ahead to 2024, our Diagnostics business is expected to maintain steady growth in line with industry standards, and our Pharma orderbook is on a record trajectory – with momentum expected to compound each quarter.” Kim Stratton continued, “We are excited to be engaged in discussions with multiple potential strategic partners and to have deepened our relationship with Lifera over the past months. With this progress at the forefront, CENTOGENE is positioned for growth and a path towards profitability. We expect to see 2024 annual revenue growth between 10-15%.” FullYear2023FinancialHighlights Total revenues increased by 2% to €48.5 million in FY2023, compared to €47.5 million in FY2022 Diagnostics segment revenues increased by 8% in 2023 to €33.7 million, primarily related to an increase of 11% in revenues for CentoXome® (CENTOGENE’s proprietary Whole Exome Sequencing) and CentoGenome® (CENTOGENE’s proprietary Whole Genome Sequencing). Achieved upselling 47% of CentoXome® and CentoGenome® orders to MOx (CENTOGENE’s portfolio of multiomic testing solutions) in FY2023 Pharma segment revenues of €14.8 million, reflecting a decrease of 8%, primarily driven by a lag in Pharma program timelines in H2 2023 Overall gross profit margin of 36% of revenues or €17.2 million in FY2023, compared to 42% of revenues or €19.8 million in FY2022 Net loss position increased by 12.2% at €35.8 million in FY2023 compared to a net loss of €31.9 million in FY2022 Total segment adjusted EBITDA was at €11.1 million in FY2023, compared to €13.2 million in FY2022. This decrease was mainly driven by the lag in pharma revenues, as well as the increase in cost of sales and selling expenses Cash and cash equivalents were €19.1 million as of December 31, 2023, compared to €35.9 million for the period ended December 31, 2022 “We are focused on streamlining processes and strengthening our financial position to enable us to execute on our leading rare and neurodegenerative disease business and sustainable long-term value creation,” said Miguel Coego, Chief Financial Officer at CENTOGENE. “Looking ahead, we will remain prudent with our capital allocation – serving as a key driver to our goal of hitting EBITDA breakeven by the end of this year and our path to cash profitability. We believe this will enable us to advance our strategic alternatives process to unlock value for our patients, physicians, pharma partners, and CENTOGENE stakeholders.” RecentBusiness Highlights Corporate Announced strategic collaboration with Lifera, a biopharmaceutical company wholly-owned by the PIF, with the formation of a joint venture (JV), Lifera Omics, to increase local and regional access and rapid delivery of world-class genomic and multiomic testing to patients in Saudi Arabia and countries of the Gulf Cooperation Council (GCC). Under the terms of the collaboration, CENTOGENE received a $30 million mandatory convertible loan from Lifera, as well as milestone payments Secured an additional approximately $20 million proceeds from Lifera via the sale of $15 million in CENTOGENE’s accounts receivables (AR) in Saudi Arabia at face value with no recourse. Additionally, Lifera purchased 16% of CENTOGENE’s stake into their JV at a value of approximately $5 million with CENTOGENE maintaining 4% ownership in the JV with the option to repurchase the previous ownership on substantially the same terms in the next 6-24 months. CENTOGENE to remain active in Lifera Omics’ operations to deliver genomic and multiomic testing Initiated strategic alternatives process focused on sustainable long-term value creation for the benefit of its stakeholders Expanded the CENTOGENE Biodatabank to over 850,000 patients, over 70% of whom are of non- European descent, approximately 30,000 active physicians, and more than 85 million unique variants thanks to the increasing number of CentoXome® and CentoGenome® analyses, which contain significantly more variants than more targeted diagnostic tests Authored over 30 peer-reviewed scientific publications in FY2023, reaching a milestone of over 300 publications in the Company’s history. The research unlocked insights into Parkinson’s disease, Gaucher disease, Niemann-Pick type C1 disease, hereditary angioedema, autosomal recessive spastic paraplegia, colorectal carcinomas, renal hypouricemia, CLN6 disease, ELOVL4-related autosomal recessive neuro-ichthyosis, CFTR-related disease, TOR1A-related disorders, as well as a range of variants associated with epilepsy, genetic cancers, metabolic disorders, developmental disorders, and other rare and neurodegenerative diseases Pharma Led 48 collaborations with 34 different pharmaceutical partners in FY2023. Of these 48 collaborations, 12 were with new partners. Starting off Q1 2024, the Company has formed collaborations with eight new partners Extended Takeda partnership to March 2026 to continue providing access to genetic testing for patients with lysosomal storage disorders Announced research project with The Michael J. Fox Foundation to validate the genetic risk factors of Parkinson’s disease using multiomics Reached initial recruitment and genetic testing milestone in the observational EFRONT Study, being conducted to advance the genetic understanding of frontotemporal dementia (FTD) Leading, alongside Denali Therapeutics, the ROPAD Study, the world’s largest observational study on Parkinson’s disease genetics with over 15,000 enrolled patients to date. Patients enrolled in ROPAD and identified with LRRK2 genetic variations may be eligible for participation in ongoing interventional clinical studies Diagnostics Strong test requests of approximately 81,500 test requests for FY2023, representing an increase of approximately 18% as compared to approximately 57,100 in the prior year Strengthened Diagnostics Sales team and expanded direct footprint distribution network in targeted geographic areas, such as Canada, Colombia, Italy, Spain, and Portugal Expanded MOx, the Company’s multiomic diagnostic portfolio, now incorporating cutting-edge transcriptomic analysis. CENTOGENE’s MOx 2.0 is a single-step multiomic solution that combines DNA sequencing, biochemical testing, and now RNA sequencing to provide physicians with the most comprehensive testing capability Launched NEW CentoGenome®, the world's most comprehensive Whole Genome Sequencing tool for diagnosis of rare and neurodegenerative diseases, which now detects Copy Number Variations associated with spinal muscular atrophy, as well as complex disease-causing variants associated with Gaucher disease and susceptibility to GBA1-related Parkinson's disease Launched CENTOGENE’s FilterTool to fuel rapid, reliable analysis for diagnosis and research of rare genetic diseases by significantly reducing time- and resource-intensive processes – enabling users to display, filter, select, and classify variants. Seamlessly integrating with CentoCloud®, CENTOGENE’s CE-marked Software as a Service (SaaS) bioinformatics pipeline, FilterTool is one of the first applications to receive CE mark under new In Vitro Diagnostic Regulation (IVDR) from the European Parliament Launched together with TWIST Bioscience three Next Generation Sequencing target enrichment panels, Twist Alliance CNTG Exome, Twist Alliance CNTG Rare Disease Panel, and Twist Alliance CNTG Hereditary Oncology Panel, to support rare disease and hereditary cancer research and support diagnostics Integrated Illumina’s new NovaSeq X Plus Sequencer into the Company’s state-of-the-art, CAP/CLIA accredited laboratory in Rostock, Germany, to further optimize throughput, scale, and cost efficiencies Published research in Science in collaboration with the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine on human pre-T cell receptor alpha (pre-TCRα) deficiency and its effect on human immunity Published study in the European Journal of Human Genetics revealing unique genetic variants in world's largest Niemann-Pick type C1 disease cohort Published the discovery of a new form of early-onset dystonia and parkinsonism in the context of neurodevelopmental abnormalities associated to the gene called ACBD6 (Acyl-CoA Binding Domain Containing 6) as part of an international team of researchers. The landmark study’s findings have been published in Brain Published a study in the Diagnostics journal establishing lyso-Gb1 (glucosylsphingosine) as a predictive biomarker 2024 Revenue Guidance The Company expects revenue growth to be between 10-15% in FY2024 compared to FY2023. Update on Process to Review Strategic Alternatives On February 28, 2024, we announced a process to explore strategic alternatives, including the sale of the Company, divestitures of asset, licensing/partnership transactions, and/or additional financing. We engaged an investment banker firm to advise us in connection with this process. We are currently in active discussions with several interested parties, which could result in a near-term transaction by July 15, 2024. We do not expect to disclose developments unless and until our board of directors has concluded that disclosure is appropriate or required. There can be no assurance that our strategic review process will result in any transaction or other strategic outcome. We do not intend to disclose further developments on this strategic review process unless and until we determine that such disclosure is appropriate or necessary. AboutCENTOGENE CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization. Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis – building a network of approximately 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is captured in our CENTOGENE Biodatabank, with over 850,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 300 peer-reviewed publications. By translating our data and expertise into tangible insights, we have supported over 50 collaborations with pharma partners. Together, we accelerate and de-risk drug discovery, development, and commercialization in target and drug screening, clinical development, market access and expansion, as well as offering CENTOGENE Biodata Licenses and Insight Reports to enable a world healed of all rare and neurodegenerative diseases. To discover more about our products, pipeline, and patient-driven purpose, visit and follow us on LinkedIn. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is designed to,” “potential,” “predict,” “objective” and similar expressions and future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “can,” and “may,” or the negative of these are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause CENTOGENE’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward- looking statements. Such risks and uncertainties include, among others, our ability to achieve the revenue levels set forth in our guidance, negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth, our ability to execute our business plan and strategy, including to enter into new client relationships, our ability to execute on our announced strategic alternatives process, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our continued ongoing compliance with covenants linked to financial instruments, including timing requirements with respect to our strategic alternatives process, our requirement for additional financing, and our ability to continue as a going concern, or other factors. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CENTOGENE’s business in general, see CENTOGENE’s risk factors set forth in CENTOGENE’s Form 20-F filed on May 15, 2024, with the Securities and Exchange Commission (the “SEC”) and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. Non-IFRS Measures This document may contain summarized, non-audited, or non-GAAP financial information. The information contained herein should therefore be considered as a whole and in conjunction with all the public information regarding the Company available, including any other documents released by the Company that may contain more detailed information. Adjusted EBITDA, adjusted EBITDA as a percentage of sales, working capital as a percentage of sales, adjusted EBITDA margin, working capital, adjusted net profit, adjusted profit per share, adjusted gross debt, and net cash/debt are non-IFRS financial metrics that management uses in its decision making. CENTOGENE has included these financial metrics to provide supplemental measures of its performance. The Company believes these metrics are important and useful to investors because they eliminate items that have less bearing on the Company’s current and future operating performance and highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. CONTACT CENTOGENE Melissa Hall Corporate Communications Press@centogene.com Lennart Streibel Investor Relations IR@centogene.com Centogene N.V. Consolidated statements of comprehensive loss for the years ended December 31, 2023, 2022 and 2021 (in EUR k) Note 2023 2022 2021 Revenue 7.2 48,536 47,473 42,234 Cost of sales 31,287 27,712 28,735 Gross profit 17,249 19,761 13,499 Research and development expenses 12,361 17,488 19,297 General administrative expenses 32,588 32,587 43,480 Selling expenses 12,564 9,924 9,326 Impairment of financial assets 812 — 827 Gain on reversal of financial asset impairment — 432 — Other operating income 8.1 11,848 3,774 2,894 Other operating expenses 8.2 431 741 86 Operating loss (29,659 ) (36,773 ) (56,623 ) Losses from investments accounted for by the Equity method 15 (302 ) — — Gains/(losses) on changes in fair value of warrants 8.3 (159 ) 2,574 — Interest and similar income 3,293 512 3 Interest and similar expenses 8,418 4,909 802 Financial costs, net 8.3 (5,284 ) (1,823 ) (799 ) Loss before taxes from continuing operations (35,245 ) (38,596 ) (57,422 ) Income taxes expenses 10 287 107 (70 ) Loss for the year from continuing operations (35,532 ) (38,703 ) (57,352 ) Net income from discontinued operations, net of tax 9 — 6,862 11,106 Loss for the period (35,532 ) (31,841 ) (46,246 ) Other comprehensive income/(loss), all attributable to equity holders of the parent (271 ) (76 ) 543 Total comprehensive loss (35,803 ) (31,917 ) (45,703 ) Attributable to: — — Equity holders of the parent (35,803 ) (31,917 ) (45,801 ) Non‑controlling interests from continuing operations 25 — — 98 Non‑controlling interests from discontinued operations — — — (35,803 ) (31,917 ) (45,703 ) Net loss per share - Basic and diluted from (in EUR) Continuing operations 11 (1.27 ) (1.45 ) (2.53 ) Loss attributable to parent 11 (1.27 ) (1.19 ) (2.04 ) The accompanying notes form an integral part of these consolidated financial statements Centogene N.V. Consolidated statements of financial position as of December 31, 2023 and 2022 (in EUR k) Assets Note Dec 31, 2023 Dec 31, 2022 Non‑current assets Intangible assets 12 6,850 7,400 Property, plant and equipment 13 5,643 6,808 Right-of-use assets 14 13,635 15,351 Investment in Joint Venture 15 2,784 — Derivative assets 23.1 799 510 Other assets 17 3,425 2,911 33,136 32,980 Current assets Inventories 16 2,463 1,819 Trade receivables and contract assets 17 19,415 16,548 Other assets 17 3,042 5,514 Cash and cash equivalents 18 19,099 35,951 44,019 59,832 77,155 92,812 Equity and liabilities Note Dec 31, 2023 Dec 31, 2022 Equity Issued capital 19 3,478 3,307 Capital reserve 19 148,308 145,369 Accumulated deficit and other reserves (177,068 ) (141,265 ) Non‑controlling interests — — (25,282 ) 7,411 Non‑current liabilities Non‑current loans 21.1 39,880 40,051 Lease liabilities 21.1 12,399 13,125 Deferred tax liabilities 10 407 35 Government grants 21.2 5,701 6,687 Derivative liabilities 21.2, 23 242 376 Warrant liability 21.2, 23 394 260 Other liabilities 21.2, 22 48 202 59,071 60,736 Current liabilities Government grants 21.2 984 1,263 Current loans 21.1 25,882 4,635 Lease liabilities 21.1 2,178 2,311 Liabilities from income taxes 87 89 Trade payables 21.2 5,628 6,317 Other liabilities 21.2, 22 8,607 10,050 43,366 24,665 77,155 92,812 The accompanying notes form an integral part of these consolidated financial statements Centogene N.V. Consolidated statements of cash flows for the years ended December 31, 2023, 2022 and 2021 (in EUR k) Note 2023 2022 2021 Operating activities Loss before taxes from continuing operations (35,245 ) (38,596 ) (57,422 ) Income before taxes from discontinued operations 9 — 6,875 11,152 Loss before taxes (35,245 ) (31,721 ) (46,270 ) Adjustments to reconcile earnings to cash flow from operating activities Amortization (including impairments) and depreciation 12,13,14 7,610 10,378 19,974 Government grant depreciation (1,265 ) — — Inventory write-off 16 226 — 1,795 Interest income 8.3 (209 ) — (3 ) Interest expense 8.3 8,201 4,909 851 Gain on the disposal of property, plant and equipment (56 ) (754 ) (18 ) Gain on the sales of IP to Joint Venture 8.1 (7,549 ) — — Expected credit loss allowances on trade receivables and contract assets 23.2 761 — 827 Share‑based payment expenses 22 2,929 (16 ) 8,035 Tax Expense — (89 ) — Profit or loss from financial instruments FV adjustments 8.3 (263 ) (2,574 ) — Loss from Joint Venture equity method 15 302 — — Other non‑cash items (34 ) (1,430 ) (821 ) Net foreign exchange differences (2,438 ) 963 — Interest received 209 — — Changes in operating assets and liabilities: Inventories 16 (870 ) 2,050 5,741 Trade receivables and contract assets 17 (3,628 ) 6,914 4,855 Other assets 17 1,858 - 1,828 Trade payables 21.2 (689 ) (4,935 ) (20,484 ) Other liabilities (1,599 ) (10,182 ) 1,952 Thereof cash flow (used in) continuing operating activities (31,749 ) (35,497 ) (42,635 ) Thereof cash flow from discontinued operating activities — 9,009 20,897 Cash flow (used in)/from operating activities (31,749 ) (26,488 ) (21,739 ) Investing activities Cash paid for investments in intangible assets 12 (2,239 ) (1,727 ) (2,787 ) Cash paid for investments in property, plant and equipment 13 (40 ) (367 ) (2,915 ) Cash paid for investment in Joint Venture 15 (4,973 ) — — Grants received for investment in property, plant and equipment 21.2 — 506 168 Cash received from the disposals of property, plant and equipment 93 855 171 Cash received from sale of IP to Joint Venture 15 9,436 — — Interest received — — 3 Thereof cash flow from/(used in) in continuing investing activities 2,277 (1,553 ) (2,494 ) Thereof cash flow from/(used in) discontinued investing activities — 820 (2,866 ) Cash flow used in investing activities 2,277 (733 ) (5,360 ) Financing activities Cash received from the issuance of shares 19 — 12,140 — Cash received from issuance of warrants — 2,833 — Cash paid for acquisition of non-wholly owned subsidiary — (1 ) — Cash received from loans 21, 23.2 25,500 40,568 1,772 Cash repayments of loans 21, 23.2 (3,374 ) — (464 ) Cash repayments of lease liabilities 21, 23.2 (3,095 ) (4,314 ) (4,244 ) Interest paid 8.3 (5,987 ) (4,909 ) (267 ) Thereof net cash flow from/(used in) continuing financing activities 13,044 46,798 (2,403 ) Thereof net cash flow used in discontinued financing activities — (481 ) (800 ) Cash flow from financing activities 13,044 46,317 (3,203 ) Changes in cash and cash equivalents (16,428 ) 19,096 (30,302 ) Cash and cash equivalents at the beginning of the period 35,951 17,818 48,156 Effect of movements in exchange rates on cash held (424 ) (963 ) (36 ) Cash and cash equivalents at the end of the period 19,099 35,951 17,818 The accompanying notes form an integral part of these consolidated financial statements